Euthymics companies are developing products for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and attention deficit and hyperactivity disorder (ADHD). According to the National Institutes of Health, MDD affects over 15 million American adults and ADHD affects nearly 10 million American adults.
Serotonin, norepinephrine, and dopamine are three important neurotransmitters found in the brain and are associated with mood, focus, cognition and pleasure. We have proprietary technology enabling us to develop single-molecule monotherapies that act on all three neurotransmitters in specific ratios optimized for each indication.
Euthymics Bioscience’s amitifadine is a serotonin-preferring triple reuptake inhibitor being evaluated for MDD in an advanced phase 2b/3a clinical trial.
Neurovance’s clinical-stage EB-1020, a norepinephrine and dopamine-preferring triple with modest activity on serotonin, is being developed for adult ADHD.
The Euthymics companies, located in Cambridge, Massachusetts, are a family of privately held companies. Euthymics Bioscience has been funded in a $28M series A venture capital investment by Novartis Venture Fund, Venture Investors, H&Q Healthcare Investors and H&Q Life Sciences Investors, GBS Venture Partners, State of Wisconsin Investment Board (SWIB) and Timothy J. Barberich. The same syndicate has funded a $7M series A1 round for Neurovance. Key members of the leadership team heading the Euthymics family of companies are experienced drug developers and have been involved in developing several of the most successful neuroscience medications for MDD and ADHD.